Company: RPID
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001380106-25-000174
Chunk: 16

Company: RAPID MICRO BIOSYSTEMS, INC.
Filing Date: 2025-08-12
Form: 10-Q
Item: Part I, Item 2
Chunk 16
---
 or 11.5%. The decrease was primarily attributable to lower service headcount and headcount-related costs.

Research and development

Three Months Ended June 30,Change20252024Amount%(dollars in thousands)Research and development$3,230 $3,744 $(514)(13.7)%Percentage of total revenue44.5 %56.6 %

Research and development expenses decreased by $0.5 million, or 13.7%. This decrease was primarily driven by engineering and development work related to our sterility application incurred during the prior year period that did not recur in the current year period.

Sales and marketing

Three Months Ended June 30,Change20252024Amount%(dollars in thousands)Sales and marketing$3,114 $3,627 $(513)(14.1)%Percentage of total revenue42.9 %54.8 %

Sales and marketing expenses decreased by $0.5 million, or 14.1%. This decrease was primarily driven by lower headcount-related and third-party consulting costs. 

General and administrative

Three Months Ended June 30,Change20252024Amount%(dollars in thousands)General and administrative$6,079 $5,818 $261 4.5 %Percentage of total revenue83.7 %87.9 %

General and administrative increased by $0.3 million, or 4.5%.  The increase was driven primarily by higher non-cash stock compensation expense. This increase was offset by lower public company operating costs. 

39

Other income (expense)

Interest income

Interest income, which is related to interest earned on our investments, decreased $0.5 million, or 58.1%, primarily as a result of lower investment balances during the three months ended June 30, 2025.

Other expense

Other expense, which is comprised of miscellaneous expenses unrelated to our core business, was flat for each of the three months ended June 30, 2025 and 2024. 

Income tax expense 

Income tax expense was less than $0.1 million for each of the three months ended June 30, 2025 and 2024. The expense in each period was attributable to income tax provisions related to our foreign subsidiaries.

Comparison of the six months ended June 30, 2025 and 2024

The following table summarizes our results of operations for the six months ended June 30, 2025 and 2024:

Six